Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C
Health care costs of persons with newly diagnosed hepatitis C virus
Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin
Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved?
Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin
Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C
Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection
Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN
Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B
The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use